Abstract:CBF beta was recently found to be a key regulator of the ability of human immunodeficiency virus type 1 (HIV-1) Vif to overcome host antiviral APOBEC3 proteins. However, the detailed molecular requirements for the Vif-CBF beta interaction are still not clear. Here, we mapped the minimum Vif domain required for CBF beta binding. In terms of CBF beta binding, the Vif N terminus was very sensitive to deletions. We determined that the Vif fragment from residues 5 to 126 was sufficient to form a stable complex with CBF beta in vitro. We also observed that ionic interactions were not the main contributor to the interaction between Vif and CBF beta. Instead, hydrophobic interactions were important for maintaining the Vif-CBF beta complex, since it could be disrupted by nonionic detergent. Site-directed mutagenesis of conserved hydrophobic amino acids revealed novel residues in Vif that were important for CBF beta binding and APOBEC3 inactivation. At least part of the well-characterized HCCH domain (residues 108 to 139) was required to form a stable Vif-CBF beta complex. Thus, the HCCH motif may have a dual role in binding both Cul5 and CBF beta. Considering the importance of Vif in HIV-1 infection, this unique Vif-CBF beta interaction represents an attractive pharmacological intervention target against HIV-1. IMPORTANCE Vif-induced APOBEC3 protein degradation was the first host antiviral mechanism against HIV-1/simian immunodeficiency virus to be revealed, yet details regarding which proteins are degraded are not fully demonstrated. Recently, host cellular factor CBF beta was found to be essential for Vif to function and promote viral infectivity. In this study, we present more critical information on the Vif-CBF beta interaction by revealing that hydrophobicity contributes the most to the Vif-CBF beta interaction and locating several novel hydrophobic sites (tryptophans and phenylalanines) that are conserved among Vif proteins from different lentiviruses and essential for Vif binding to CBF beta. Mutations on these sites result in a reduced/abolished Vif-CBF beta interaction, leading to the attenuated potency of Vif on both inducing the degradation of antiviral factors like APOBEC3G and promoting HIV-1 infectivity. Therefore, information from this study will help people to further understand how Vif acts against host antiviral mechanism, which is important for novel anti-HIV-1 drug development.

Three-dimensional Structure of HIV-1 VIF Constructed by Comparative Modeling and the Function Characterization Analyzed by Molecular Dynamics Simulation

Characterization of the Interaction of Full-Length HIV-1 Vif Protein with Its Key Regulator CBFβ and CRL5 E3 Ubiquitin Ligase Components

Structural Insight into the Human Immunodeficiency Virus Vif Socs Box and Its Role in Human E3 Ubiquitin Ligase Assembly

Structural basis of HIV-1 Vif-mediated E3 ligase targeting of host APOBEC3H

Structural Basis For Hijacking Cbf-Beta And Cul5 E3 Ligase Complex By Hiv-1 Vif

Modeling the Intracellular Dynamics for Vif-APO Mediated HIV-1 Virus Infection

Importance of the proline-rich multimerization domain on the oligomerization and nucleic acid binding properties of HIV-1 Vif

Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.

Identification of HIV-1 Vif regions required for CBF-β interaction and APOBEC3 suppression.

Design of Vif-Derived Peptide Inhibitors with Anti-HIV-1 Activity by Interrupting Vif-CBFβ Interaction

Dispersed and conserved hydrophobic residues of HIV-1 Vif are essential for CBFβ recruitment and A3G suppression.

Structural Basis of Antagonism of Human APOBEC3F by HIV-1 Vif

Conserved interaction of lentiviral Vif molecules with HIV-1 Gag and differential effects of species-specific Vif on virus production.

Requirement of HIV-1 Vif C-terminus for Vif-CBF-β Interaction and Assembly of CUL5-containing E3 Ligase

Characterization of a novel Cullin5 binding domain in HIV-1 Vif.

Evolutionarily Conserved Pressure for the Existence of Distinct G2/M Cell Cycle Arrest and A3H Inactivation Functions in HIV-1 Vif.

Association of Human Immunodeficiency Virus Type 1 Vif with RNA and Its Role in Reverse Transcription.

Design, Synthesis and Biological Evaluation of Indolizine Derivatives As HIV-1 VIF–ElonginC Interaction Inhibitors

Structural insights into PPP2R5A degradation by HIV-1 Vif

Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif

Evolutionarily Conserved Requirement for Core Binding Factor Beta in the Assembly of the Human Immunodeficiency Virus/Simian Immunodeficiency Virus Vif-Cullin 5-RING E3 Ubiquitin Ligase